Authenticated Lung Cancer Cell Lines for Cancer Research

Lung cancer is the leading cause of cancer-related death. Patients are frequently diagnosed at an advanced stage due to a relative lack of clinical symptoms. Lung cancer accounts for 13.2% of all new cancers and 25.9% of all cancer deaths each year. The overall five-year survival rate of lung cancer is lowest (18.1%) when compared to most other cancers1, but prognosis varies dramatically with pathological classification, disease stage, and patient demographics such as gender and age at diagnosis.

Types of lung cancer

The pathological classification of lung cancer is evolving. It is currently histopathologically classified into small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC)—which includes squamous cell carcinoma and adenocarcinoma.  NSCLC, sometimes referred to as large cell lung carcinoma, accounts for the majority (85%) of lung cancer diagnoses.

 

NSCLC (Frequency: 85%) SCLC (Frequency: 15%)
Squamous cell carcinoma
  • Arises from the proximal airway; more closely correlated with smoking than other NSCLC
  • Origin: Bronchial epithelium cells that line airways
Adenocarcinomas
  • Arise from the distal airway; dominant subtype in nonsmoking patients
  • Origin: mucus-producing glands and cells
Small-cell lung cancer
  • Arises from neuroendocrine cells due to heavy carcinogen exposure.
  • Origin: Tracheal basal cell progenitors, pulmonary neuroendocrine cells2
Cell lines: PC9, LO68, LUDLU-1, COR-L105, SKLU1, SKMES1, NCI-H727, LC-2/AD, NCIH358, ChaGo-K-1, MOR/CPR, MOR/0.4R, MOR/0.2R, NCIH-322 Cell lines: H69, H69V, CORL-47, COR-L51, COR-L88, DMS53, DMS79, DMS454, COR-L311, COR L303, COR-L95, NCI-H69/CPR, NCI-H69/LX4, NCI-H69/LX10 , NCI-H69/LX20, SHP-77, NCI-H510A, DMS92, DMS153, COR-L279, DMS 273

Risk factors

The incidence of lung cancer is declining in developed countries, due in part to smoking education and regulation. Incidence rates are rising, however, in less developed countries. That 80% of men and 50% of women with lung cancer are smokers demonstrates smoking as the lifestyle risk factor. Environmental risk factors include passive smoke exposure, air pollution, and other sources of particulate inhalation.

Mutations

Genetic predisposition amplifies the risk of lung cancer, and lung adenocarcinoma is more associated than other histotypes with genetic factors. The most frequently reported somatic mutations in lung cancer are in the genes for TP53, LRP1B, KRAS, KEAP1, KMT2C, FAT4, CDKN2A, EGFR, and FAT2.

Select cell lines from the table below based on mutation, and click on genes to find relevant products (antibodies, shRNA, siRNA, primers, CRISPR plasmids) for your research application.

 

Small molecules/monoclonal antibodies

Small molecule compounds and antibodies can be used to target specific cancer cells and block tumor growth and progression. The most common drugs used to target lung cancer include:

Applications

Cancer cell lines have been at the heart of cancer research, and provide an accessible, cost-effective model for cellular behavior and response. Based on the characteristics of the cell line and experimental need, cell lines may be used in one or more applications. Some examples of application-specific use for cell lines associated with lung cancer are included below.

 

Application Cell line used
Drug response studies PC-9, a lung adenocarcinoma cell line employed to study effects of small molecule inhibitors
Target identification/validation A549, a cell line model of NSCLC used to evaluate the role of CCL22 and IL-37 in epithelial-mesenchymal transition3
Toxicology studies Cellular toxicity of carbon-based nanomaterials was tested in CALU-1 and other lung cancer cell lines4
Growth factor signaling NCI-H292 (human airway epithelium cells) were employed to study the role of cigarette smoking in the pathogenesis of COPD5
Metastasis studies Human small cell lung cancer cell line DMS273 was used as a model to study metastasis6
Xenograft models Effect of ganetespib/erlotinib therapy was evaluated in non-small cell lung cancer (NCI-H322) xenograft tumors7
In vitro models BEAS-2B cell lines derived from human bronchial epithelial cells were used as in vitro models to study carcinogenesis of heavy metals8
miRNA regulation studies The biological role of miR-223 was investigated in PC-9  cell line9

 

ECACC Lung Cancer Cell Lines
 

Product No. Cell Name Cell Line Origin
86012804 A549 Human Caucasian lung carcinoma
10092305 AB1 Mouse malignant mesothelioma
10092306 AB12 Mouse malignant mesothelioma
10092307 AB22 Mouse malignant mesothelioma
10092308 AC29 Mouse malignant mesothelioma
10092310 AE17 Mouse malignant mesothelioma
6032203 BICR 3 Alveolus squamous cell carcinoma
4072111 BICR 78 Oral alveolus squamous carcinoma
93120818 CALU 1 Human Caucasian lung epidermoid carcinoma
96020948 ChaGo-K-1 Human lung bronchus carcinoma
10032301 CMT 64 Mouse lung carcinoma; metastasis
86082105 CMT64/61 Mouse C57BL/1CRF lung carcinoma
10032302 CMT 167 (clone of CMT 64) Mouse lung carcinoma; metastasis
87061209 COLO 668 Human lung oat cell carcinoma
96042336 COR-L 23/CPR Human Caucasian lung, large cell carcinoma
92031919 COR-L23 Human Caucasian lung large cell carcinoma
96042338 COR-L23/5010 Human Caucasian lung, large cell carcinoma, drug resistant
96042339 COR-L23/R Human Caucasian lung large cell carcinoma
96020740 COR-L26 Human large cell lung cancer bone marrow aspirate
92031918 COR-L105 Human Caucasian lung adenocarcinoma
96020724 COR-L279 Human lung small cell carcinoma
96020722 COR-L303 Human lung small cell carcinoma
96020721 COR-L311 Human lung small cell carcinoma
92031915 COR-L47 Human Caucasian small cell lung carcinoma
92031916 COR-L51 Human Caucasian lung carcinoma
92031917 COR-L88 Human Caucasian lung small cell carcinoma
96020733 COR-L95 Human lung small cell carcinoma
95062823 DMS 53 Human Caucasian lung small cell carcinoma
95062824 DMS 79 Human lung small cell carcinoma
95062825 DMS 92 Human Caucasian lung small cell carcinoma, metastasis to bone marrow
95062827 DMS 153 Human Caucasian lung small cell carcinoma, metastasis to liver
95062830 DMS 273 Human lung, small cell carcinoma
95062832 DMS 454 Human Caucasian lung, small cell carcinoma
6092006 H400 Human oral squamous cell carcinoma, alveolar process
91091802 H69 Human Caucasian lung small cell carcinoma
91091803 H69V Human lung small cell carcinoma
10092309 JU77 Human malignant mesothelioma
90040512 LA-4 Mouse A/He lung adenoma
94072247 LC-2/ad Human lung adenocarcinoma
90020104 LL/2(LLc1) Mouse C57BL Lewis lung carcinoma
10092311 LO68 Human malignant mesothelioma
92012463 LUDLU-1 Human Caucasian lung squamous cell carcinoma
90062272 Meta 7 Mouse TS/A lung metastases
90062271 Meta 10 Mouse TS/A lung metastases
90062270 Meta 15 Mouse TS/A lung metastases
86020603 MiCL1 (S+L-) Mink lung, Moloney murine sarcoma virus infected
84112312 MOR Human lung adenocarcinoma
96042335 MOR/0.2R Human lung adenocarcinoma, drug-resistant
96042334 MOR/0.4R Human lung adenocarcinoma, drug-resistant
96042328 NCI-H69/CPR Human small cell lung cancer, drug-resistant
96042331 NCI-H69/LX10 Human small cell lung cancer, drug-resistant
96042332 NCI-H69/LX20 Human Caucasian small cell lung carcinoma
96042329 NCI-H69/LX4 Human Caucasian small cell lung carcinoma, drug-resistant
96042330 NCI-H69VCR/R Human small cell lung cancer, drug-resistant
96042333 MOR/CPR Human lung adenocarcinoma, drug-resistant
91091815 NCI-H292 Human lung, mucoepidermoid carcinoma
95111734 NCI-H322 Human Caucasian bronchioalveolar carcinoma
95111733 NCI-H358 Human Caucasian bronchioalveolar carcinoma
96020944 NCI-H510A Human lung carcinoma, adrenal gland metastasis
94060303 NCI-H727 Human lung non-small cell carcinoma
90071810 PC-14 Human adenocarcinoma, differentiated
98110201 SHP-77 Human Caucasian lung small cell carcinoma, large cell variant
93120835 SK LU 1 Human Caucasian lung adenocarcinoma
93120837 SK MES 1 Human Caucasian lung squamous carcinoma
85011440 U937 Human Caucasian histiocytic lymphoma
87020406 V79-HG04 Hamster Chinese embyro lung fibroblast transformed

References

  1. https://seer.cancer.gov/statfacts/html/lungb.html.
  2. Hanna, J. M., and Onaitis, M. W. (2013) Cell of origin of lung cancer. J. Carcinog. 12, 6.
  3. Chen, Y.H., Zhou, B.Y., Wu, X.J., Xu, J.F., Zhang, J.A., Chen, Y.H., and Liang, S.S. (2016) CCL22 and IL-37 inhibit the proliferation and epithelial-mesenchymal transition process of NSCLC A549 cells. Oncol. Rep. 36, 2017–2024.
  4. Magrez, A., Kasas, S., Salicio, V., Pasquier, N., Seo, J. W., Celio, M., Catsicas, S., Schwaller, B., and Forró, L. (2006) Cellular toxicity of carbon-based nanomaterials. Nano Lett. 6, 1121–1125.
  5. Shao, M. X. G., Nakanaga, T., and Nadel, J. A. (2004) Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor-alpha-converting enzyme in human airway epithelial (NCI-H292) cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 287, L420-427.
  6. Sakamoto, S., Inoue, H., Ohba, S., Kohda, Y., Usami, I., Masuda, T., Kawada, M., and Nomoto, A. (2015) New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice. Cancer Sci. 106, 367–374.
  7. Smith, D. L., Acquaviva, J., Sequeira, M., Jimenez, J.P., Zhang, C., Sang, J., Bates, R. C., and Proia, D. A. (2015) The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Target. Oncol. 10, 235–245.
  8. Park, Y.H., Kim, D., Dai, J., and Zhang, Z. (2015) Human bronchial epithelial BEAS-2B cells, an appropriate in vitro model to study heavy metals induced carcinogenesis. Toxicol. Appl. Pharmacol. 287, 240–245.
  9. Zhao, F.-Y., Han, J., Chen, X.-W., Wang, J., Wang, X.-D., Sun, J.-G., and Chen, Z.-T. (2016) miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor. Int. J. Mol. Med. 38, 183–191.